TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis
Brief Summary: This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on hemodialysis. Eligible patients receiving once-weekly intravenous (IV) darbepoetin alfa maintenance treatment will be randomized to receive either intravenous Mircera once a month (at a starting dose of 120, 200 or 360 micrograms/month, depending on the weekly dose of darbepoetin alfa prior to start of study) or intravenous darbepoetin alfa every 2 weeks before switching to once monthly administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
B: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
C: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa
D: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis
Brief Summary: This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on hemodialysis. Eligible patients receiving once-weekly intravenous (IV) darbepoetin alfa maintenance treatment will be randomized to receive either intravenous Mircera once a month (at a starting dose of 120, 200 or 360 micrograms/month, depending on the weekly dose of darbepoetin alfa prior to start of study) or intravenous darbepoetin alfa every 2 weeks before switching to once monthly administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin
B: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa
C: Arm Label: MIRCERA; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): MIRCERA
D: Arm Label: Peginesatide 0.025 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Peginesatide 0.04 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.025 mg/kg | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide 0.04 mg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin Alfa

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management; A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Obese Patients
Brief Summary: The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the end of the second year of treatment (Week 104)


Options:
A: Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo
B: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes
C: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg BID | Arm Label: Matching Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo BID | Intervention Type: DRUG; Name: Lorcaserin 10 mg BID; Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo BID; Assigned to Arm(s): Matching Placebo BID

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)
Brief Summary: Asthma is a common, serious illness among children in the United States. While a low dose of inhaled corticosteroids (ICS) may effectively control symptoms, some children may require additional medications to maintain adequate asthma control. This study compares the effectiveness of a higher dose of ICS, ICS combined with a long-acting beta-agonist (LABA) medication, and ICS combined with a leukotriene receptor antagonist (LTRA) medication at reducing the impact and severity of asthma exacerbations that occur in children with mild to moderate persistent asthma.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1
B: Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6
C: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52 weeks in subjects with type 2 diabetes. Liraglutide will be compared to placebo, in combination with SU. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.


Options:
A: Arm Label: 0.6 mg + SU; Type: EXPERIMENTAL; Interventions: Drug: sulfonylurea, Drug: liraglutide | Arm Label: 0.9 mg + SU; Type: EXPERIMENTAL; Interventions: Drug: sulfonylurea, Drug: liraglutide | Arm Label: SU Mono - 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: sulfonylurea | Arm Label: SU Mono - 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sulfonylurea | Intervention Type: DRUG; Name: sulfonylurea; Assigned to Arm(s): 0.6 mg + SU, 0.9 mg + SU, SU Mono - 1, SU Mono - 2 | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): 0.6 mg + SU | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): 0.9 mg + SU
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glibenclamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: glibenclamide, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: glibenclamide; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glibenclamide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide
C: Arm Label: Saxagliptin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Saxagliptin | Arm Label: Glipizide; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Sulphonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glipizide, Saxagliptin | Intervention Type: DRUG; Name: Sulphonylurea; Assigned to Arm(s): Glipizide | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: add-on pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: add-on sulphonylurea | Intervention Type: DRUG; Name: add-on pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: add-on sulphonylurea; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.
Brief Summary: The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
D: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.
Brief Summary: The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.


Options:
A: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4
B: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Intervention Type: DRUG; Name: clopidogrel (SR25990C); Assigned to Arm(s): N/A
D: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): Enoxaparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.
Brief Summary: The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.


Options:
A: Arm Label: Arm I (apixaban); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Other: Questionnaire Administration | Arm Label: Arm II (dalteparin); Type: EXPERIMENTAL; Interventions: Drug: Dalteparin, Other: Questionnaire Administration | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm I (apixaban) | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Arm II (dalteparin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (apixaban), Arm II (dalteparin)
B: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis The Einstein-DVT Dose-finding Study. A Phase II Evaluation.
Brief Summary: The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.


Options:
A: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
B: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4
C: Arm Label: BAY59-7939; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Standard of Care; Type: EXPERIMENTAL; Interventions: Drug: Standard of Care | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): BAY59-7939 | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Standard of Care
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: B